Recruiting Now in Eugene Or
New Migraine Clinical Trials in Eugene Or
Medically Reviewed By
Dr. Sarah Jensen, MD, Board-Certified Rheumatologist
Residents of Eugene Or, OR struggling with Migraine may qualify for a new investigational treatment study being conducted by leading Eugene Or facilities.
No Insurance Needed
Identify New Options
Am I Eligible?
Check if you qualify for the Up to $1,200 compensation.
Diagnosed with Migraine?
Aged 18-65?
Live near Eugene Or?
100% Free • No Insurance Required
FDA Guidelines Monitored
HIPAA Compliant Data
256-bit SSL Enrollment
Local Medical Insight
Clinical research for Migraine in Eugene Or is supported by major OR medical networks and research universities, ensuring state-of-the-art care and oversight for all participants in Eugene Or.
Location
The research center is conveniently located in Eugene Or. Validation parking is provided for all visits. (Specific address revealed upon qualification).
Qualification
- Age 18 - 65
- Diagnosed with Migraine
- Trying to find better management options
Available Trials in Eugene Or
NCT06077838(Verify on ClinicalTrials.gov)
RELAXaHEAD for Headache Patients (Phase III)
RECRUITINGMigraine
NCT05158894(Verify on ClinicalTrials.gov)
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
RECRUITINGMigraine
NCT06735833(Verify on ClinicalTrials.gov)
MMA Embolization for Refractory Chronic Migraine
RECRUITINGMigraine
Environmental Factors in Eugene Or
Living in Eugene Or presents unique lifestyle factors that can influence the management of Migraine. Local weather patterns and urban stressors are important considerations for ongoing clinical research.
Patient FAQ: Eugene Or
Is travel compensation available?
Yes, many trials in the area provide stipends for travel expenses.
Do I need insurance?
No, all study-related care and medication are provided at no cost.
Can I keep my current doctor?
Absolutely. Study participation is a supplemental care option.